Daniel Allen Gold - 16 Sep 2026 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Reporting relationship: Director
Issuer ticker: ROIV
Reported as of: 16 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Sep 2026, 19:12:51 UTC
Prior SEC filing: 14 Sep 2026
Source filing: View source filing
Reporting owner signature: By: /s/ Sam Kaplan, as Attorney-in-Fact for Daniel Gold

Key filing fact

Daniel Allen Gold filed Form 4 for Roivant Sciences Ltd. (ROIV) on 18 Sep 2026.

Key facts

This page summarizes Daniel Allen Gold's Form 4 filing for Roivant Sciences Ltd. (ROIV).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Sep 2026, 19:12.

Change

Previous filing in this sequence was filed on 14 Sep 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001832142 Primary reporting owner

Gold Daniel Allen

Relationship: Director
Address: C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM
Signature: By: /s/ Sam Kaplan, as Attorney-in-Fact for Daniel Gold
Signature date: 18 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ROIV transaction

Common Shares

Award

Transaction value
Shares: +5,054
Change %: +0.06%
Price: $0.000000^*
Shares after: 8,965,815
Date: 16 Sep 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ROIV transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +10,531
Change %
Price: $0.000000^*
Shares after: 10,531
Date: 16 Sep 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 10,531
Exercise price: $39.57
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.

Footnote F2

Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.